688331 荣昌生物
已收盘 07-22 15:00:00
资讯
新帖
简况
荣昌生物(09995.HK)泰它西普获批准用于治疗类风湿关节炎患者
阿斯达克财经 · 16分钟前
荣昌生物(09995.HK)泰它西普获批准用于治疗类风湿关节炎患者
荣昌生物(09995):泰它西普(商品名:泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者
智通财经 · 07-22 19:22
荣昌生物(09995):泰它西普(商品名:泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者
荣昌生物获得实用新型专利授权:“一种核酸印迹转膜装置”
证券之星 · 07-19
荣昌生物获得实用新型专利授权:“一种核酸印迹转膜装置”
荣昌生物(09995)股价下跌5.083%,现价港币$16.06
阿斯达克财经 · 07-18
荣昌生物(09995)股价下跌5.083%,现价港币$16.06
荣昌生物(688331)7月17日主力资金净买入360.60万元
证券之星 · 07-18
荣昌生物(688331)7月17日主力资金净买入360.60万元
荣昌生物(09995)上涨5.13%,报17.2元/股
金融界 · 07-17
荣昌生物(09995)上涨5.13%,报17.2元/股
荣昌生物(09995)股价上升5.012%,现价港币$17.18
阿斯达克财经 · 07-17
荣昌生物(09995)股价上升5.012%,现价港币$17.18
生物科技概念盘中拉升,荣昌生物涨3.82%
自选股智能写手 · 07-17
生物科技概念盘中拉升,荣昌生物涨3.82%
北向资金7月16日净买入荣昌生物11.22万股 连续3日增持
自选股智能写手 · 07-17
北向资金7月16日净买入荣昌生物11.22万股 连续3日增持
荣昌生物(09995.HK)实际控制人增持18万A股 金额511万人民币
阿斯达克财经 · 07-17
荣昌生物(09995.HK)实际控制人增持18万A股 金额511万人民币
7月16日荣昌生物发布公告,其股东增持18万股
证券之星 · 07-16
7月16日荣昌生物发布公告,其股东增持18万股
荣昌生物(09995)实际控制人控制的企业累计增持18万股公司股份 涉资510.9万元
智通财经 · 07-16
荣昌生物(09995)实际控制人控制的企业累计增持18万股公司股份 涉资510.9万元
荣昌生物(688331.SH)获实控人控制企业累计增持18万股
智通财经 · 07-16
荣昌生物(688331.SH)获实控人控制企业累计增持18万股
港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长
智通财经 · 07-16
港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长
港股异动 | 荣昌生物(09995)跌超3% RC18出海进度慢于预期 市场担忧公司现金流情况
智通财经网 · 07-15
港股异动 | 荣昌生物(09995)跌超3% RC18出海进度慢于预期 市场担忧公司现金流情况
荣昌生物07月15日遭主力抛售883万元 环比增加146.65%
自选股智能写手 · 07-15
荣昌生物07月15日遭主力抛售883万元 环比增加146.65%
【券商聚焦】建银国际削荣昌生物(09995)目标价11.76% 指RC18授权许可问题为近期最大挑战
金吾财讯 · 07-15
【券商聚焦】建银国际削荣昌生物(09995)目标价11.76% 指RC18授权许可问题为近期最大挑战
透过这场高峰论坛,看到ADC下一个level
荣昌生物 · 07-15
透过这场高峰论坛,看到ADC下一个level
荣昌生物(688331)7月12日主力资金净卖出581.68万元
证券之星 · 07-13
荣昌生物(688331)7月12日主力资金净卖出581.68万元
荣昌生物股价异动,实控人急抛增持计划提振市场信心
新京报网 · 07-12
荣昌生物股价异动,实控人急抛增持计划提振市场信心
加载更多
公司概况
公司名称:
荣昌生物制药(烟台)股份有限公司
所属行业:
医药制造业
上市日期:
2022-03-31
主营业务:
荣昌生物制药(烟台)股份有限公司是一家具有全球化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。公司主营业务是发现、开发与商业化创新、有特色的同类首创(first-in-class)与同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。公司的核心产品为泰它西普、维迪西妥单抗、RC28。
发行价格:
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":28.44,"timestamp":1721631600000,"preClose":27.96,"halted":0,"volume":3720973,"delay":0,"floatShares":162000000,"shares":544000000,"eps":-2.8225,"marketStatus":"已收盘","marketStatusCode":5,"change":0.48,"latestTime":"07-22 15:00:00","open":27.91,"high":28.87,"low":27.8,"amount":106000000,"amplitude":0.0383,"askPrice":28.48,"askSize":2,"bidPrice":28.44,"bidSize":32,"shortable":0,"etf":0,"ttmEps":-2.8225,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":27.96,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":30.76,"lowLimit":25.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":544332083,"pbRate":5.03,"roa":"--","roe":"--","epsLYR":-2.8,"committee":-0.127072,"marketValue":15481000000,"floatMarketCap":4606000000,"peRate":-10.076174,"changeRate":0.0172,"turnoverRate":0.023,"status":0,"afterMarket":{"amount":0,"volume":0,"close":28.44,"buyVolume":0,"sellVolume":0,"time":1721633637153,"indexStatus":"已收盘 07-22 15:30:00","preClose":27.96}},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2453718721","title":"荣昌生物(09995.HK)泰它西普获批准用于治疗类风湿关节炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2453718721","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453718721?lang=zh_cn&edition=full","pubTime":"2024-07-23 00:51","pubTimestamp":1721667060,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布,泰它西普(商品名:泰爱)正式获得中国国家药品监督管理局在中国上市的完全批准,用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普是集团专有用于治疗自身免疫性疾病的新型融合蛋白,产品已于2023年11月正式获得中国国家药品监督管理局在中国的完全上市批准,用于治疗系统性红斑狼疮。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-22 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1365404/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2328871848.SGD","09995","LU1064130708.USD","BK1583","LU2148510915.USD","BK0239","LU1064131003.USD","BK1574","LU1969619763.USD","BK1161","688331"],"gpt_icon":0},{"id":"2453766908","title":"荣昌生物(09995):泰它西普(商品名:泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2453766908","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453766908?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:22","pubTimestamp":1721647341,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荣昌生物 发布公告,泰它西普正式获得中国国家药品监督管理局在中国上市的完全批准,用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普在本适应症获得批准,是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究,共入组479例患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU1064131003.USD","688331","BK0239","BK1583","LU1969619763.USD","BK1161","BK1574","LU1064130708.USD","LU2148510915.USD","09995"],"gpt_icon":0},{"id":"2452458567","title":"荣昌生物获得实用新型专利授权:“一种核酸印迹转膜装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452458567","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452458567?lang=zh_cn&edition=full","pubTime":"2024-07-19 02:17","pubTimestamp":1721326631,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示荣昌生物新获得一项实用新型专利授权,专利名为“一种核酸印迹转膜装置”,专利申请号为CN202322939094.6,授权日为2024年7月19日。今年以来荣昌生物新获得专利授权7个,较去年同期增加了16.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900002550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0239","BK1583","LU1064130708.USD","LU1064131003.USD","09995","LU2148510915.USD","LU2328871848.SGD","BK1161","688331","BK1574"],"gpt_icon":0},{"id":"2452175053","title":"荣昌生物(09995)股价下跌5.083%,现价港币$16.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2452175053","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452175053?lang=zh_cn&edition=full","pubTime":"2024-07-18 15:23","pubTimestamp":1721287380,"startTime":"0","endTime":"0","summary":"[下跌股]荣昌生物(09995) 股价在下午03:23比前收市价下跌5.083%,现股价为港币$16.06。至目前为止,今日最高价为$17.04,而最低价为$16.04。总成交量为134.15万股,总成交金额为港币$2.199千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407181389/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1064130708.USD","BK1574","LU2328871848.SGD","BK0239","09995","LU2148510915.USD","LU1064131003.USD","BK1161","688331","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2452597112","title":"荣昌生物(688331)7月17日主力资金净买入360.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452597112","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452597112?lang=zh_cn&edition=full","pubTime":"2024-07-18 08:13","pubTimestamp":1721261637,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月17日收盘,荣昌生物报收于29.36元,上涨2.8%,换手率2.29%,成交量3.71万手,成交额1.08亿元。近5日资金流向一览见下表:荣昌生物融资融券信息显示,融资方面,当日融资买入269.97万元,融资偿还206.87万元,融资净买入63.1万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800012965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","LU2328871848.SGD","LU2148510915.USD","688331","LU1064130708.USD","LU1064131003.USD","BK0239","09995","LU1969619763.USD","BK1583","BK1574"],"gpt_icon":0},{"id":"2452859441","title":"荣昌生物(09995)上涨5.13%,报17.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452859441","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452859441?lang=zh_cn&edition=full","pubTime":"2024-07-17 14:50","pubTimestamp":1721199014,"startTime":"0","endTime":"0","summary":"7月17日,荣昌生物(09995)盘中上涨5.13%,截至14:50,报17.2元/股,成交2303.37万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物,主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处,已创制出一批具有重大临床价值的生物新药。截至2024年一季报,荣昌生物营业总收入3.3亿元、净利润-3.49亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17145041616360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688331","BK0239","09995","BK1161","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD","BK1574","LU2328871848.SGD","BK1583","LU1064130708.USD"],"gpt_icon":0},{"id":"2452627185","title":"荣昌生物(09995)股价上升5.012%,现价港币$17.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2452627185","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452627185?lang=zh_cn&edition=full","pubTime":"2024-07-17 14:50","pubTimestamp":1721199000,"startTime":"0","endTime":"0","summary":"[上升股]荣昌生物(09995) 股价在下午02:50比前收市价上升5.012%,现股价为港币$17.18。至目前为止,今日最高价为$17.18,而最低价为$16.3。总成交量为136.8万股,总成交金额为港币$2.303千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407171268/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","09995","LU1064130708.USD","688331","BK1583","LU1064131003.USD","BK1161","LU2148510915.USD","BK1574","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2452901455","title":"生物科技概念盘中拉升,荣昌生物涨3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452901455","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452901455?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:01","pubTimestamp":1721192508,"startTime":"0","endTime":"0","summary":"07月17日,生物科技概念盘中拉升,截至13点01分,生物科技概念整体指数上涨1.00%,报680.280点。从个股上来看,该概念的成分股中,荣昌生物涨3.82%,沃森生物、智飞生物、奥浦迈涨幅居前。从资金上来看,截止发稿,生物科技概念主力净流入为1430.72万,其中智飞生物受到资金热捧,主力净流入1844.78万;拉长时间线来看,该板块近20日主力资金净流入-11.21亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717130148aefa0e20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717130148aefa0e20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","BK1161","BK1583","LU1969619763.USD","LU2328871848.SGD","BK1574","688331"],"gpt_icon":0},{"id":"2452795299","title":"北向资金7月16日净买入荣昌生物11.22万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452795299","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452795299?lang=zh_cn&edition=full","pubTime":"2024-07-17 09:30","pubTimestamp":1721179838,"startTime":"0","endTime":"0","summary":"7月16日, 北向资金增持荣昌生物11.22万股,连续3日增持。截止当日收盘,沪股通共持有荣昌生物347.37万股,占流通股2.14%。荣昌生物近5个交易日下跌1.01%,沪股通累计增持76.00万股;近20个交易日下跌40.13%,沪股通累计增持145.37万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170937419f5a16fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170937419f5a16fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU1064131003.USD","688331","LU1064130708.USD","BK0239","LU2148510915.USD"],"gpt_icon":0},{"id":"2452123910","title":"荣昌生物(09995.HK)实际控制人增持18万A股 金额511万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2452123910","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452123910?lang=zh_cn&edition=full","pubTime":"2024-07-17 00:51","pubTimestamp":1721148660,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布,7月9日至16日,实际控制人通过彼控制的企业烟台荣昌控股在上海证券交易所系统以集中竞价方式累计增持公司18万,金额共计511万人民币,超过本次增持计划下限金额1,000万人民币的50%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-16 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364083/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1064131003.USD","09995","LU1969619763.USD","BK1161","159982","BK1583","LU2148510915.USD","LU2328871848.SGD","BK1574","LU1064130708.USD","399300","688331","BK0239"],"gpt_icon":0},{"id":"2451608439","title":"7月16日荣昌生物发布公告,其股东增持18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451608439","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451608439?lang=zh_cn&edition=full","pubTime":"2024-07-16 19:00","pubTimestamp":1721127659,"startTime":"0","endTime":"0","summary":"证券之星消息,7月16日荣昌生物发布公告《荣昌生物:荣昌生物制药(烟台)股份有限公司关于实际控制人控制的企业增持公司股份的进展公告》,其股东烟台荣昌控股集团有限公司于2024年7月9日至2024年7月16日间合计增持18.0万股,占公司目前总股本的0.0331%,变动期间该股股价下跌20.8%,截止7月16日收盘报28.56元。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600037402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0239","BK1583","LU1064130708.USD","LU1064131003.USD","09995","LU2148510915.USD","LU2328871848.SGD","BK1161","688331","BK1574"],"gpt_icon":0},{"id":"2451964790","title":"荣昌生物(09995)实际控制人控制的企业累计增持18万股公司股份 涉资510.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451964790","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451964790?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:30","pubTimestamp":1721125853,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荣昌生物(09995)公布实际控制人控制的企业增持公司股份的进展,2024 年 7 月 9 日至 2024 年 7 月 16 日,公司实际控制人王威东、房健民、林健、王荔强、王旭东、邓勇、熊晓滨、杨敏华、温庆凯、魏建良通过其控制的企业烟台荣昌控股集团有限公司通过上海证券交易所系统以集中竞价方式累计增持公司股份18万股,占公司总股本的 0.0331%,合计增持金额为人民币 510.9万元(不含交易费用),已超过本次增持计划下限金额人民币 1000 万元的 50%,本次增持计划尚未实施完毕。烟台荣昌控股集团有限公司将继续按照相关增持计划,在增持计划实施期限内增持公司股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2148510915.USD","LU1064131003.USD","BK1574","LU1969619763.USD","LU1064130708.USD","688331","09995","BK1583","LU2328871848.SGD","BK0239"],"gpt_icon":0},{"id":"2451961808","title":"荣昌生物(688331.SH)获实控人控制企业累计增持18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451961808","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451961808?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:03","pubTimestamp":1721124218,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荣昌生物(688331.SH)发布公告,2024年7月9日至2024年7月16日,公司实际控制人王威东、房健民、林健、王荔强、王旭东、邓勇、熊晓滨、杨敏华、温庆凯、魏建良通过其控制的企业烟台荣昌控股集团有限公司通过上海证券交易所系统以集中竞价方式累计增持公司股份18万股,占公司总股本的0.0331%,合计增持金额为510.9万元(不含交易费用),已超过本次增持计划下限金额1000万元的50%,本次增持计划尚未实施完毕。烟台荣昌控股集团有限公司将继续按照相关增持计划,在增持计划实施期限内增持公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1064130708.USD","688331","BK1583","09995","BK1161","LU2148510915.USD","BK0239","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2451954372","title":"港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2451954372","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451954372?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:46","pubTimestamp":1721115990,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物现涨超3%,截至发稿,涨3.39%,报16.46港元,成交额1785.43万港元。消息面上,7月8日和9日,荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。该行指,国家医保目录为关键产品销售增长提供避风港。该行称, 2024年内主要催化剂为RC18潜在出海,若能完成,则有助于显著提升股价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1064130708.USD","688331","07226","BK1583","HSCEI","YANG","09995","BK1161","LU2148510915.USD","BK0239","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","HSTECH"],"gpt_icon":0},{"id":"2451645692","title":"港股异动 | 荣昌生物(09995)跌超3% RC18出海进度慢于预期 市场担忧公司现金流情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2451645692","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451645692?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:25","pubTimestamp":1721028320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物跌超3%,截至发稿,跌3.17%,报15.88港元,成交额1600.37万港元。消息面上,浦银国际研报指出,7月8日和9日,荣昌生物A股、H股分别累计下跌27%、35%,主要系在目前脆弱的市场情绪下,RC18出海进度不及预期,加大了投资者对公司现金流情况的担忧。管理层称RC18出海仍具挑战性,未来将开放性考虑多种出海方式。该行称, 2024年内主要催化剂为RC18潜在出海,若能完成,则有助于显著提升股价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","LU2328871848.SGD","BK1574","LU1064130708.USD","BK0239","688331","BK1583","LU1064131003.USD","LU1969619763.USD","HSCEI","LU2148510915.USD","09995","07226","HSTECH","YANG"],"gpt_icon":0},{"id":"2451303692","title":"荣昌生物07月15日遭主力抛售883万元 环比增加146.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451303692","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451303692?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:18","pubTimestamp":1721027905,"startTime":"0","endTime":"0","summary":"07月15日, 荣昌生物股价跌1.85%,报收28.06元,成交金额1.34亿元,换手率2.90%,振幅3.85%,量比0.50。荣昌生物今日主力资金净流出883万元,上一交易日主力净流出358万元,今日环比增加146.65%。该股近5个交易日下跌22.19%,主力资金累计净流出1856万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出7623万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151526329f4d564c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151526329f4d564c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0239","LU1064131003.USD","688331","LU2148510915.USD"],"gpt_icon":0},{"id":"2451693830","title":"【券商聚焦】建银国际削荣昌生物(09995)目标价11.76% 指RC18授权许可问题为近期最大挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2451693830","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451693830?lang=zh_cn&edition=full","pubTime":"2024-07-15 13:31","pubTimestamp":1721021489,"startTime":"0","endTime":"0","summary":"基于首季营收,预测其2024年第二季度总营收将同比增长50%至3.76亿元人民币,上半年总营收将同比增长69%至7.07亿元人民币。维持2024财年调整后净亏损预测不变,但将2025财年的调整后净亏损预测从9.55亿元人民币上调至11亿元人民币,2026财年从1.27亿元人民币上调至4.11亿元人民币。维持“跑赢大市”评级,目标价由34港元下调至30港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940381","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2451666524","title":"透过这场高峰论坛,看到ADC下一个level","url":"https://stock-news.laohu8.com/highlight/detail?id=2451666524","media":"荣昌生物","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451666524?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:06","pubTimestamp":1721009169,"startTime":"0","endTime":"0","summary":"2021年6月9日,中国首个原创ADC药物维迪西妥单抗获批上市。新型ADC药物掀开了胃癌精准治疗新篇章,HER2在胃癌治疗中成为最受关注的靶点之一。该临床研究首次在HER2阳性和HER2低表达胃癌患者中探索了靶向HER2-ADC药物联合免疫治疗的安全性和疗效。维迪西妥单抗联合免疫及化疗一线治疗晚期胃癌也显示了惊艳的结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151034509f4bf899&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151034509f4bf899&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","09995","BK1574","688331","BK1161","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2451451598","title":"荣昌生物(688331)7月12日主力资金净卖出581.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451451598","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451451598?lang=zh_cn&edition=full","pubTime":"2024-07-13 08:11","pubTimestamp":1720829484,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月12日收盘,荣昌生物报收于28.59元,上涨6.36%,换手率4.7%,成交量7.61万手,成交额2.17亿元。近5日资金流向一览见下表:荣昌生物融资融券信息显示,融资方面,当日融资买入357.44万元,融资偿还1389.67万元,融资净偿还1032.23万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071300012284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2328871848.SGD","BK1583","BK1161","BK0239","LU1969619763.USD","688331","LU1064130708.USD","09995","LU2148510915.USD","BK1574"],"gpt_icon":0},{"id":"2450894301","title":"荣昌生物股价异动,实控人急抛增持计划提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2450894301","media":"新京报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450894301?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:29","pubTimestamp":1720776540,"startTime":"0","endTime":"0","summary":"继股价连续三个交易日大幅下跌后,7月11日,荣昌生物实控人抛出增持计划提振市场信心,本次增持金额不低于1000万元且不超过2000万元。7月11日,荣昌生物在股票异常波动公告中表示,经自查,公司目前生产经营活动一切正常,市场环境、行业政策没有发生重大调整,生产成本和销售等情况没有出现大幅波动,内部生产经营秩序正常。7月9日当晚,荣昌生物实控人抛出增持计划提振市场信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712173013aef96bd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712173013aef96bd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688331","LU1064130708.USD","LU2148510915.USD","09995","LU1064131003.USD"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":-0.3962},{"period":"3month","weight":-0.4717},{"period":"6month","weight":-0.3442},{"period":"1year","weight":-0.5525},{"period":"ytd","weight":-0.5417}],"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","perCapita":"30006股","boardName":"医药制造业","registeredCapital":"54433万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 荣昌生物制药(烟台)股份有限公司是一家具有全球化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。公司主营业务是发现、开发与商业化创新、有特色的同类首创(first-in-class)与同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。公司的核心产品为泰它西普、维迪西妥单抗、RC28。","serverTime":1721668012236,"listedPrice":48,"stockholders":"5397人(较上一季度减少11.83%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}